Leuprorelin acetate

Bezeichnung:Leuprorelin acetate

CAS-Nr74381-53-6

Englisch Name:Leuprorelin acetate

CBNumberCB7174300

SummenformelC61H88N16O14

Molgewicht1269.47

MOL-Datei74381-53-6.mol

Leuprorelin acetate physikalisch-chemischer Eigenschaften

Schmelzpunkt	150-155°C
storage temp.	-20°C
Löslichkeit	DMSO (Slightly), Methanol (Slightly)
Aggregatzustand	Solid
Farbe	White to Off-White
Merck	14,5457
InChIKey	RGLRXNKKBLIBQS-XNHQSDQCSA-N

Sicherheit

S-Sätze:	22-24/25
WGK Germany	2
RTECS-Nr.	OH6390000
HS Code	29371900

Gefahreninformationscode (GHS)

Leuprorelin acetate Chemische Eigenschaften,Einsatz,Produktion Methoden

S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
Beschreibung
Leuprolide acetate is a potent analog of LH-RH useful in achieving a medical castration in the treatment of advanced prostate cancer. It has also been investigated for the treatment of advanced breast cancer.
Chemische Eigenschaften
Fluffy Solid
Originator
Takeda (Japan)
Verwenden
Leuprolide acetate USP (Leupron) is used to treat Prostatic carcinoma.
Verwenden
In mice, leuprolide acetate salt has been used to check the need of estrogen receptor α in spermatogenic cells, for development or function in fertilization.
Verwenden
Synthetic nonapeptide agonist analog of LH-RH. Antineoplastic (hormonal).
Definition
ChEBI: An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the t eatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.
Manufacturing Process
5-Oxo-L-prolyl-L-histidyl-L-tryptophanyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-Larginyl-L-prolylethylamideacetate was prepared by using of Boc strategy on a 2%-crosslinking chloromethylated divinylbenzene-styrene copolymer in a the Merrifield automatic sintesizer apparatus. 4.6 g of this resin/aminoacid material is used for the synthesis of the desired nonapeptide. Each N-blocked aminoacid is added in a three-fold access and allowed to couple to them, existing aminoacid-resin ester in the usual coupling cycle. Ordinarily the solvent used for the coupling reaction is dichloromethane or, when the solubility of the blocked aminoacid is low, a mixture of dichloromethane and DMF. Coupling is effected by the addition of a solution of dicyclohexylcarbodiimide in dichloromethane at a 2.9 fold excess. The sequence used for deprotection, neutralization and coupling of the next aminoacid is done in a fully automatic system. In this manner, the peptide is assembled using in turn Boc-Arg(Tos), Boc-Leu, Boc-D-Leu, Boc-Tyr(Cl2Bzl), Boc-Ser(Bzl), Boc-Trp, Boc-His(DNP), and pGlu wherein all aminoacids are in the L-form except in the leucine so designated. A 250 mg sample of the above is placed in a hydrogen fluoride reaction with 250 mg vessel of anisole and about 5 ml of anhydrous hydrogen fluoride is distilled into it. After 1 hour at 0°C, the hydrogen fluoride is removed with a stream of dry nitrogen and the residue is taken up in 1% acetic acid. This solution is extracted with ether, and the aqueous phase applied to a 1 time 30 cm column of a highly basic ion exchange resin (marketed by Bio-Rad as AGl resin) in the acetate form. The product is eluted with 0.1 N acetic acid and localized using thin-layer chromatography (CHCl3/MeOH/32% HOAc: 120/90/40, silica gel G, Cl2/tolidine). The product bearing solution is lyophilized, rechromatographed on a Sephadex G-25 (marketed by Pharmacia of Uppsala, Sweden) column. The product eluted is collected and lyophilized to yield a fluffy white solid. An aminoacid analysis shows the expected ratio of all desired aminoacids assembled in the above fashion.
Trademarks
Eligard (QLT); Lupron(TAP); Viadur (ALZA);CARCINIL.
Therapeutic Function
Antineoplastic
Biochem/physiol Actions
Glp-His-Trp-Ser-Tyr-Leu-Leu-Arg-Pro-NHEt (des-Gly10-[D-Leu6]-LH-RH) is a GnRH (gonadotropin-releasing hormone) agonist, leuprolide. GnRH (Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), which is also referred as LHRH (luteinizing hormone-releasing hormone) or gonadorelin, is crucial for mammalian reproduction and is released from hypothalamic neurons. It is responsible for the secretion of gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), from the pituitary glands. Mutations in GnRH are associated with normosmic congenital hypogonadotropic hypogonadism. Low concentration of leuprolide can be used for the treatment of endometriosis, uterine fibroids, central precocious puberty and advanced prostate cancer.
Pharmakologie
Leuprolide, 5-oxo-L-prolyl-L-histadyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucil-L-leucil-L-arginyl-N-ethyl-L-prolinamide (30.5.9), is made synthetically.
pyroGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt
The nonapeptide leuprolide is a synthetic analog of the decapeptide, gonadotropin releasing hormone, and it exceeds the activity of the natural hormone and significantly elevates the level of testosterone and dihydrotestosterone in men, and estrogen in women. It also inhibits follicle-stimulating hormone and leutenizing hormone.
Leuprolide is used for prostate cancer, when orchiectomy or estrogen therapy is counterproductive to the patient. A synonym of this drug is lupron.
Clinical Use
Leuprolide acetate, a synthetic nonapeptide analogue of GnRH that possesses greater potency than the natural hormone, is a superagonist that is commercially available. Note that leuprolide acetate contains substitutions that hinder enzymatic degradation, D-Leu and NH-Et in place of Gly6 and Gly10-NH2, respectively. Leuprolide acetate is reportedly 15-fold the potency of natural GnRH. When given continuously and in therapeutic doses, leuprolide acetate inhibits LH and FSH secretion by desensitizing/downregulating the GnRH receptors. After an initial stimulation, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. In premenopausal females, estrogens are reduced to postmenopausal levels; in males, testosterone is reduced to castrate levels.
Leuprolide acetate is administered by daily injections or as depot injections every month, every 3 months, every 4 months, or every 6 months as a palliative treatment in advanced prostatic carcinoma (as an alternative to orchiectomy). An implant version (Viadur) also is available for long-term palliative therapy; after implantation of the device into the upper arm, leuprolide acetate is continuously released over a 12-month period. Because dihydrotestosterone, a metabolite of testosterone, is able to stimulate the growth of prostate cancer, the ability of leuprolide acetate to bring testosterone to near castrate levels is why this drug finds use as a palliative in the advanced disease. The addition of a nonpeptidyl antiandrogen, such as flutamide or bicalutamide, to the leuprolide acetate regimen inhibits adrenal and testicular synthesized androgens from binding to or being taken up by target prostate cancer tissue. This combination therapy helps to control the initial flare-up, by blocking all sources of androgen, and is referred to as maximal androgen blockade.
Leuprolide acetate, in monthly and every-3-months depot formulations, is useful in treating women diagnosed with endometriosis, but not for longer than six months because of the chance of developing osteoporosis.
Central precocious puberty that is idiopathic, or gonadotropin dependent, can cause the development of secondary sexual characteristics in girls before the age of 8 years and in boys before the age of 9 years. In addition to the psychological and physiological changes that occur because of entering puberty too early, there is the risk of the child failing to reach his or her full adult height. Therefore, leuprolide acetate's ability to suppress LH and sex steroid levels (testosterone and estradiol) to prepubertal levels is the reason that leuprolide acetate is approved for use in treating children with this disease. Use of this drug in a child with precocious puberty will slow or stop that child's secondary sexual development, slow linear growth and skeletal maturation, and in girls, will bring about the cessation of menstruation.
Nebenwirkungen
Side effects: allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue; breathing problems; chest pain; depression or memory disorders; pain in your legs or groin; pain at site where injected or implanted; seizures; severe headache; signs and symptoms of high blood sugar such as being more thirsty or hungry or having to urinate more than normal. You may also feel very tired or have blurry vision; swelling of the feet and legs; suicidal thoughts or other mood changes; visual changes; vomiting
Arzneimittelwechselwirkung
Leuprorelin acetate can not take with mang drugs, such as chasteberry, cisapride, dronedarone, pimozide, or thioridazine. This medicine may also interact with the following medications: herbal or dietary supplements, like black cohosh or DHEA; female hormones, like estrogens or progestins and birth control pills, patches, rings, or injections; male hormones, like testosterone; other medicines that prolong the QT interval (abnormal heart rhythm).

Leuprorelin acetate Upstream-Materialien And Downstream Produkte

Leuprorelin acetate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

74381-53-6, Leuprorelin acetate Verwandte Suche:

Send Inquriy